Amgen, Inc. (AMGN) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its position in Amgen, Inc. (NASDAQ:AMGN) by 15.2% during the third quarter, HoldingsChannel.com reports. The firm owned 205,853 shares of the medical research company’s stock after buying an additional 27,181 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Amgen were worth $42,671,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of AMGN. Beutel Goodman & Co Ltd. acquired a new position in Amgen in the 2nd quarter valued at about $86,723,000. Mutual Advisors LLC grew its stake in Amgen by 5.8% in the 2nd quarter. Mutual Advisors LLC now owns 4,814 shares of the medical research company’s stock valued at $889,000 after buying an additional 265 shares during the last quarter. Lederer & Associates Investment Counsel CA grew its stake in Amgen by 2.4% in the 3rd quarter. Lederer & Associates Investment Counsel CA now owns 13,150 shares of the medical research company’s stock valued at $2,726,000 after buying an additional 310 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Amgen by 2.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock valued at $592,025,000 after buying an additional 72,205 shares during the last quarter. Finally, Argent Trust Co grew its stake in Amgen by 31.8% in the 2nd quarter. Argent Trust Co now owns 11,691 shares of the medical research company’s stock valued at $2,159,000 after buying an additional 2,818 shares during the last quarter. 77.91% of the stock is currently owned by institutional investors.

Shares of NASDAQ:AMGN opened at $208.25 on Friday. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $210.19. The company has a market cap of $132.70 billion, a price-to-earnings ratio of 16.55, a price-to-earnings-growth ratio of 2.16 and a beta of 1.37. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. During the same quarter in the prior year, the business posted $3.27 EPS. The business’s revenue was up 2.3% compared to the same quarter last year. Equities analysts expect that Amgen, Inc. will post 14.24 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.54%. The ex-dividend date is Thursday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.

A number of brokerages recently commented on AMGN. Royal Bank of Canada reiterated a “neutral” rating and issued a $193.00 price target on shares of Amgen in a research note on Monday, September 10th. Jefferies Financial Group reiterated a “buy” rating and issued a $220.00 price target on shares of Amgen in a research note on Monday, October 1st. Oppenheimer reiterated a “buy” rating and issued a $224.00 price target on shares of Amgen in a research note on Tuesday, August 28th. Wells Fargo & Co reiterated a “neutral” rating and issued a $197.00 price target on shares of Amgen in a research note on Wednesday, August 29th. Finally, Citigroup upped their price target on shares of Amgen from $200.00 to $204.00 and gave the company a “neutral” rating in a research note on Thursday, November 1st. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $204.55.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/12/02/amgen-inc-amgn-shares-bought-by-zurcher-kantonalbank-zurich-cantonalbank.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit